PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, reports further developments with its Joint Venture Company, XGEN Medical LLC (�XGen�) towards implementing operations in the United Arab Emirates (U.A.E.).
Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. (See, 17 August 2010 Press Release) Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.
During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries.
XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.
It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of Proteonomix’s proprietary cellular materials for treatment of disease.
Cereplast, Inc. (NASDAQ: CERP), a leading manufacturer of proprietary bio-based, compostable and sustainable plastics, has partnered with Sezersan Ambalaj (Sezersan), a subsidiary of Asci Group in Turkey, to produce bio twist films made from Cereplast Compostables resins. The first-of-its-kind, patented product will serve as wrap packaging for a variety of food products distributed throughout Europe.
The Sezersan bio twist film will be manufactured using Cereplast Compostables 7003 bio resin, designed to provide high strength, toughness and process ability for products. Under the terms of the multi-million dollar agreement, Cereplast will begin monthly shipments of 100 to 150 metric tons of bio resin in December 2010. The new bio twist film has substantial form memory capability (dead-fold behavior) and is heat sealable. The film is also thinner than other twistable product and may be made into opaque or semi-transparent, film-like material. The bio twist film will be used as packaging for a variety of brands in the food industry in Europe.
“Cereplast bio resins will help us cater to consumer demand for an environmentally sound substitute for petroleum-based plastic packaging,” said Mehmet Asci, President and CEO of Asci Group. �As one of the largest twist film producing companies in Europe, we are committed to listening to the concerns of our clients and to finding ways to improve our product offerings. Cereplast resin allows us to provide an environmentally intelligent alternative to traditional plastic products, helping to make the world a healthier place. We are excited to be the very first to offer this solution in our robust industry.�
Cereplast, Inc. is actively producing bioplastic resins for use in products including tableware, cutlery, toys, healthcare and hygiene products, bottles and containers, bags, packaging, gift cards, printed displays, straws, pipes, conduits, and many other applications. This year, Cereplast is on track to ship 16 million pounds of bio-plastic resins to customers around the world, an increase of 400% from last year, in response to surging consumer and industrial demand for economically and ecologically sound, “green” products.
Cerner Corporation (Nasdaq:CERN) reports results for the 2010 second quarter that ended July 3, 2010, delivering strong levels of bookings, revenue, earnings and cash flow.
Bookings in the second quarter of 2010 were $467.8 million, up 19 percent from $394.0 million in the second quarter of 2009. Second quarter revenue was $456.0 million, up 13 percent compared to $403.8 million in the year-ago period.
On a Generally Accepted Accounting Principles (GAAP) basis, second quarter 2010 net earnings were $55.5 million, and diluted earnings per share were $0.65. Second quarter 2009 GAAP net earnings were $43.8 million, and diluted earnings per share were $0.52.
Cerner is transforming healthcare by eliminating error, variance and waste for healthcare providers and consumers around the world. Cerner solutions optimize processes for healthcare organizations ranging in size from single-doctor practices, to health systems, to entire countries, for the pharmaceutical and medical device industries, employer health and wellness services industry and for the healthcare commerce system.
These solutions are licensed by more than 8,500 facilities around the world, including approximately 2,300 hospitals; 3,400 physician practices covering more than 30,000 physicians; 600 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 700 home-health facilities; and 1,500 retail pharmacies.
Cerus Corporation (NASDAQ:CERS) reports a favorable outcome of a large French study evaluating transfusion of over 13,000 platelet components treated with the INTERCEPT Blood System. The study has just been published online in the journal Transfusion1.
“This study demonstrates that INTERCEPT can be implemented into routine practice, providing protection against transfusion-transmitted pathogens, without impacting either platelet or red blood cell utilization. This observation confirms previous data indicating that the treated platelets are functioning similarly to untreated platelets,” said Dr. Laurence Corash, Cerus’ chief medical officer. “The investigators also noted that use of INTERCEPT treated platelets resulted in a decrease in the incidence of adverse events following transfusion.”
The study was performed by the Etablissement Fran�ais du Sang (EFS) of Alsace, France, which is the sole provider of blood components for the region’s approximately two million inhabitants. EFS Alsace, which produces approximately 17,000 platelet components per year, implemented production of INTERCEPT platelets in 2006. In order to assess the impact of their conversion to pathogen inactivated platelets, the blood center performed a retrospective analysis of routinely collected active hemovigilance data collected both before and after the change. Collection of hemovigilance data is mandatory in France, and the system is estimated to collect data from over 99% of all transfusions. The study also evaluated the center’s introduction of platelet additive solution, which occurred prior to conversion to INTERCEPT. Three periods of data were compared, including in total over 33,000 platelet transfusions to almost 6000 patients.
The EFS Alsace study results are consistent with those reported in several other large post-marketing evaluations of INTERCEPT platelets2-4, and also similar to a previously published multi-year Belgian experience5. Like most INTERCEPT customers, EFS Alsace is able to realize some cost offsets by using the inactivation treatment in place of gamma irradiation for prevention of transfusion-associated graft-versus-host disease, in place of cytomegalovirus testing, and in place of bacterial detection tests.
No comments:
Post a Comment